Open Government Portal

Found 10 records similar to About MedEffect Canada

Federal

MedEffect Canada provides consumers, patients, and health professionals with easy access to report an adverse reaction or side effect

Last Updated: Apr. 28, 2022
Date Published: Dec. 30, 2021
Organization: Health Canada
Formats: HTML
Keywords:  MedEffect Canada, report on adverse-reaction, report on side-effect
Federal

MedEffect Canada uses a variety of mechanisms to share information and to help you stay informed about advisories and recalls that are issued by Health Canada, as well as by Industry, for health products, such as pain relievers, cold medicines, prescription drugs, medical devices, vaccines and natural health products.

Last Updated: Apr. 28, 2022
Date Published: Oct. 13, 2020
Organization: Health Canada
Formats: HTML
Keywords:  MedEffect Canada, report on adverse-reaction, report on side-effect, stay informed
Federal

This document provides guidance on the study and analysis of sex differences in clinical trials of therapeutic products in order to generate evidence to advise on the optimal use of therapeutic products in both women and men.

Last Updated: Sep. 17, 2020
Date Published: May 4, 2017
Organization: Health Canada
Formats: HTML
Keywords:  Inclusion of Women in Clinical Trials, analysis of sex differences in clinical trials, therapeutic products, optimal use of therapeutic products in both women and men.
Federal

This document provides guidance on the study and analysis of sex differences in clinical trials of therapeutic products in order to generate evidence to advise on the optimal use of therapeutic products in both women and men.

Last Updated: Jun. 2, 2021
Date Published: Dec. 10, 2013
Organization: Health Canada
Formats: HTML
Keywords:  guidance document, inclusion of women, inclusion of women in clinical trials, analysis of sex differences, sex differences in clinical trials, therapeutic products, optimal use of therapeutic products
Federal

Cannabis is not an approved therapeutic product and the provision of this information should not be interpreted as an endorsement of the use of cannabis for therapeutic purposes, or of marijuana generally, by Health Canada. This leaflet is designed by Health Canada for patients authorized to possess cannabis for medical purposes.

Last Updated: Jun. 27, 2022
Date Published: Nov. 30, 2018
Organization: Health Canada
Formats: HTML
Keywords:  cannabis, marihuana, marijuana, consumer information, therapeutic product, use of cannabis, cannabis for therapeutic-purposes, patients authorized-to-possess cannabis, cannabis for medical-purposes
Federal

The Canadian Medical Devices Sentinel Network (CMDSNet) is a pro-active surveillance program that encourages the reporting of medical device problem reports from all types of institutions.

Last Updated: Apr. 28, 2022
Date Published: Jun. 25, 2019
Organization: Health Canada
Formats: HTML
Keywords:  MedEffect Canada, report on adverse-reaction, report on side-effect, stay informed, Canadian-Medical-Devices Sentinel Network
Federal

This document has been prepared by the Cannabis Legalization and Regulation Branch at Health Canada to provide information on the use of cannabis (marihuana) and cannabinoids for medical purposes. This document is a summary of peer-reviewed literature and international reviews concerning potential therapeutic uses and harmful effects of cannabis and cannabinoids.

Last Updated: Jun. 27, 2022
Date Published: Jul. 2, 2021
Organization: Health Canada
Formats: HTML
Keywords:  information for health-care-professionals, cannabis, marihuana, marijuana, cannabinoids, cannabinoids for medical-purposes, therapeutic uses, harmful effects-of cannabis, harmful effects-of cannabinoids
Federal

Health Canada, the federal regulatory authority that evaluates the quality, safety, and efficacy of human drugs available in Canada, recognizes that there are circumstances in which sponsors cannot reasonably provide substantial evidence demonstrating the safety and efficacy of a therapeutic product as there are logistical or ethical challenges in conducting the appropriate human clinical trials. The Extraordinary Use New Drugs (EUND) pathway was developed to allow a mechanism for authorization of these drugs based on non-clinical and limited clinical information.

Last Updated: Jun. 7, 2022
Date Published: Mar. 3, 2022
Organization: Health Canada
Formats: HTML
Keywords:  extraordinary use New-Drugs, EUNDs, submission information requirements, quality-safety-efficacy of human-drugs, safety-efficacy of therapeutic-products, ethical challenges, human clinical trials, non-clinical information, limited clinical information
Federal

The Health and Biosciences Sector Regulatory Review Roadmap outlined a number of regulatory modernization commitments. These included plans to modernize the regulations for clinical trials and advanced therapeutic products (ATPs).

Last Updated: Jun. 7, 2022
Date Published: Jan. 25, 2021
Organization: Health Canada
Formats: HTML
Keywords:  agile regulations, advanced therapeutic products, clinical trials, Health-and-Biosciences Sector, regulatory review roadmap, regulatory modernization commitments, modernize-the-regulations for clinical-trials, advanced therapeutic products, ATPs
Federal

The Medical Devices Bureau of the Therapeutic Products Directorate (TPD) is the national authority that monitors and evaluates the safety, effectiveness and quality of diagnostic and therapeutic medical devices in Canada.

Last Updated: Sep. 17, 2020
Date Published: May 18, 2017
Organization: Health Canada
Formats: HTML
Keywords:  Safe medical devices.
Date modified: